Drugs / LAM-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03426605 | Jan 2018 → Feb 2020 | acute myeloid leukemia | OrphAI Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAM-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426605 ↗ |
| Route | Oral | “Subjects will self-administer oral LAM-003 either once or twice per day” NCT03426605 ↗ |